Authors showed that the time to insulin requirement was significantly longer among patients (n = 11) who received sitagliptin shortly after the occurrence of hyperglycemia, as compared to patients (n = 15) who did not receive any oral or non-insulin injectable glucose-lowering medications until insulin was clearly required to manage hyperglycemia [137]. The gene discussed is INS; the disease is Hyperglycemia.